Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 164-167

  Garrido, Carolina ^a   Soriano, Vincent ^a   Geretti, Anna Maria ^b   Zahonero, Natalia ^a   Garcia, Silvia ^a   Booth, Clare ^b   Gutierrez, Felix ^c   Viciana, Isabel ^d   de Mendoza, Carmen ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Hospital General Universitario   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Dolutegravir; Drug resistance; HIV subtypes; Integrase; Raltegravir; S GSK1349572

Indexed keywords

DOLUTEGRAVIR; GSK 1349572; INTEGRASE INHIBITOR; RALTEGRAVIR; S 1349572; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; VIRUS MUTATION;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; PYRROLIDINONES; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953882562     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.03.178     Document Type: Article

References (19)

1. Ceccherini-Silberstein F., Van Baelen K., Armenia D., Trignetti M., Rondelez E., Fabeni L., Scopelliti F., Pollicita M., Van Wesenbeeck L., Van Eygen V., Dori L., Sarmati L., Aquaro S., Palamara G., Andreoni M., Stuyver L.J., Perno C.F. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob. Agents Chemother. 2010, 54:3938-3948.
2. Eron, J., Livrozet, J.M., Morlat, M., Lazzarin, A., Katlama, C., Hawkins, T., Fujiwara, T., Cuffe, R., Vavro, C., Santiago, J., Ait-Khaled, M., Min, S., Yeo, J.M., 2010a. Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: Week 24 results of the VIKING study (ING112961) [abstract O435]. In: Program and abstracts of Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom.
3. Eron J.J., Young B., Cooper D.A., Youle M., Dejesus E., Andrade-Villanueva J., Workman C., Zajdenverg R., Fätkenheuer G., Berger D.S., Kumar P.N., Rodgers A.J., Shaughnessy M.A., Walker M.L., Barnard R.J., Miller M.D., Dinubile M.J., Nguyen B.Y., Leavitt R., Xu X., Sklar P. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010, 375:396-407. SWITCHMRK 1 and 2 investigators.
4. Fransen S., Karmochkine M., Huang W., Weiss L., Petropoulos C.J., Charpentier C. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of HIV type 1 during virologic failure. Antimicrob. Agents Chemother. 2009, 53:4522-4524.
5. Garrido C., Geretti A.M., Zahonero N., Booth C., Strang A., Soriano V., De Mendoza C. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J. Antimicrob. Chemother. 2010, 65:320-326.
6. Johns, B., Kawasuji, T., Taishi, T., Yoshida, H., Garvey, E., Spreen, W., Underwood, M., Sato, A., Yoshinaga, T., Fujiwara, T., 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile [abstract 55]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
7. Kobayashi M., Nakahara K., Seki T., Miki S., Kawauchi S., Suyama A., Wakasa-Morimoto C., Kodama M., Endoh T., Oosugi E., Matsushita Y., Murai H., Fujishita T., Yoshinaga T., Garvey E., Foster S., Underwood M., Johns B., Sato A., Fujiwara T. Selection of diverse and clinically relevant integrase inhibitor-resistant HIV type 1 mutants. Antiviral Res. 2008, 80:213-222.
8. Kobayashi, M., Seki, T., Morimoto, C., Yoshinaga, T., Sato, A., Fujiwara, T., Johns, B., Underwood, M., 2010. S/GSK1349572, a next generation integrase inhibitor (INI), has potential for a high genetic barrier to resistance based on in vitro passage study [abstract 31]. In: Program and Abstracts of the 8th European HIV Drug Resistance Workshop, Sorrento, Italy.
9. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., Barnard R.J., Miller M.D., DiNubile M.J., Nguyen B.Y., Leavitt R., Sklar P. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806. STARTMRK investigators.
10. Malet I., Delelis O., Soulie C., Wirden M., Tchertanov L., Mottaz P., Peytavin G., Katlama C., Mouscadet J.F., Calvez V., Marcelin A.G. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J. Antimicrob. Chemother. 2009, 63:795-804.
11. Marcelin, A.G., Malet, I., Fabeni, L., Armenia, D., Fourati, S., Masquelier, B., Katlama, C., Perno, C.F., Calvez, V., Ceccherini-Silberstein, F., 2010. Resistance-associated mutations to integrase inhibitor S/GSK1349572 in HIV-1 integrase inhibitor-naïve and raltegravir-experienced patients [abstract 554]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
12. Martínez E., Larrousse M., Llibre J.M., Gutiérrez F., Saumoy M., Antela A., Knobel H., Murillas J., Berenguer J., Pich J., Pérez I., Gatell J.M. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010, 2411:1697-1707. SPIRAL Study Group.
13. Rockstroh, J., Felizarta, F., Maggiolo, F., Pulido, F., Stellbrink, H.J., Tsybakova, O., Yeni, P., Almond, S., Brothers, C., Song, I., Min, S., 2010. Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: Rapid and potent 24-week antiviral responses in SPRING-1 (ING112276) [abstract O434]. In: Program and Abstracts of Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.
14. Sato, A., Kobayashi, M., Yoshinaga, T., Fujiwara, T., Underwood, M., Johns, B., Foster, S., Hazen, R., Ferris, R., Brown, K., Garvey, E., 2009. S/GSK1349572 is a potent next generation HIV integrase inhibitor [abstract WEPEA097]. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
15. Sato, A., Kobayashi, M., Seki, T., Morimoto, C.W., Yoshinaga, T., Fujiwara, T., Johns, B.A., Underwood, M., 2010. S/GSK1349572: A next generation integrase inhibitor (INI) with limited or no-cross resistance to first generation INIs or other classes of antivirals [abstract 29]. In: Program and Abstracts of the 8th European HIV Drug Resistance Workshop. Sorrento, Italy.
16. Seki, T., Kobayashi, M., Wakasa-Morimoto, C., Yoshinaga, T., Sato, A., Fujiwara, T., Underwood, M., Garvey, E., Johns, B., 2010. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [abstract 555]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
17. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Meibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Nguyen B.Y., Teppler H. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:339-354. BENCHMRK Study Teams.
18. Underwood, M., Johns, B., Sato, A., Fujiwara, T., Spreen, W., 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on Raltegravir therapy [abstract WEPEA098]. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
19. Vispo E., Barreiro P., Maida I., Mena A., Blanco F., Rodríguez-Novoa S., Morello J., Jimenez-Nacher I., Gonzalez-Lahoz J., Soriano V. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin. Trials 2010, 11:197-204.